In a Morning Consult commentary, IVI Executive Director, Jennifer Bright, discusses why transparency is a prerequisite to value-based reimbursement and how IVI's Open-Source Value Platform (OSVP) is an open laboratory for creating sophisticated systems to assess value in healthcare. Read the full article here.
In an article published online by the American Journal of Managed Care, IVI's Executive Director, Jennifer Bright, and Director of Scientific Communications, Mark Linthicum, offer five predictions for where value assessment is headed in 2019. Specifically, Jennifer and Mark focus their discussion on the following areas of interest regarding value assessment: Including patient perspectives becomes [...]
Value Frameworks Must Incorporate Real-World Evidence, Says Research Team Including IVI’s Darius Lakdawalla and Wayne Burton
In a new paper published by the American Journal of Managed Care, a team of researchers, including IVI's Darius Lakdawalla and Wayne Burton, conclude that key decision makers within our healthcare system need to recognize the importance of implementing real-world evidence and devote resources to further research into the chronic disease areas in which the [...]
In an interview with the Journal of Clinical Pathways, IVI's Jennifer Bright and Mark Linthicum discuss how IVI is transforming value assessment. Read the transcript from the interview here.
In an article published on AJMC.com, IVI'sJennifer Bright discusses how IVI makes incorporating patients' perspectives a priority in developing open-source, transparent value models. Read the full article here.
In an article published on AJMC.com, IVI'sJennifer Bright and Mark Linthicum argue value assessment stakeholders need to have transparent discussions about value assessment and understand what value means from other points of view. Read the full article here.
Precision Benefit Design: How should the arrival of precision medicine affect health plan benefit design?
Advances in precision medicine offer the promise of tremendous gains in patient health over the coming decades. Headlines in the popular press as well as discussions at academic conferences tout the potential benefits of precision medicine, while at the same time critiquing the nascent but growing evidence base and the high cost of treatment. One [...]
While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI's Jennifer Bright and Mark Linthicum address this concern in a recent article for the American Journal of Managed Care (AJMC). Read the [...]
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI's Jennifer Bright (Executive Director) and Mark Linthicum (Director [...]
IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, "The neat 'answer' regarding the value of treatment [...]